Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Nanoparticles Analysis in Lung and Bronchi During Various Pulmonary Interstitial Diseases and Relationships With Their Aetiology (NANOPI)

11. September 2015 aktualisiert von: Centre Hospitalier Universitaire de Saint Etienne

Nanoparticles Analysis in Lung and Bronchi During Various Pulmonary Interstitial Diseases and Relationships With Their Aetiology. A Monocentric Study

Nanoparticles (NP) are particles whose length, width and height are less than 100 nanometres. Over the past decade, industrial applications of NP have increased dramatically. Despite their widespread use, their true impact on human health remains unknown and poorly studied. NP exposure in humans primarily occurs via inhalation through the respiratory system. The aim of this study is to estimate the relationships between the nanoparticle load in the lung and bronchi and some interstitial lung diseases. In the aftermath of human exposure to asbestos, the pathological consequences of environmental exposure to nanomaterials could be evaluated upon a mineralogical analysis of pulmonary samples.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Interstitielle Lungenerkrankungen

Intervention / Behandlung

Studientyp

Beobachtungs

Einschreibung (Tatsächlich)

100

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

Frankreich
- - Saint-Etienne, Frankreich, 42055
    - CHU Saint-Etienne

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Wahrscheinlichkeitsstichprobe

Studienpopulation

" Test group ": patients suffering from idiopathic interstitial lung diseases including sarcoidosis and idiopathic pulmonary fibrosis.
" Control group ": patients suffering from interstitial lung diseases of known aetiologies, such as hypersensibility pneumonitis, infectious or cancerous interstitial diseases and interstitial diseases caused by drug reactions.

Beschreibung

Inclusion Criteria:

Patients with an interstitial lung disease assessed on clinical signs and CT scan, requiring a flexible bronchoscopy with a broncho-alveolar lavage.

These patients suffer from:

Idiopathic interstitial lung diseases such as idiopathic pulmonary fibrosis or sarcoidosis OR
Interstitial lung diseases of known aetiologies such as hypersensibility pneumonitis, infectious or cancerous interstitial diseases and interstitial diseases caused by drug reactions.

Written consent

Exclusion Criteria:

Flexible bronchoscopy or BAL not possible.
Pregnant women
Patients under legal protection.
Patients with contagious disease (HIV infection, tuberculosis, viral hepatitis)

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Anzahl der Gruppen / Kohorten

Kohorten und Interventionen

Gruppe / Kohorte	Intervention / Behandlung
Idiopathic interstitial diseases " Test group ": patients suffering from idiopathic interstitial lung diseases including sarcoidosis and idiopathic pulmonary fibrosis. Nanoparticles (NP) loads will be measured on Bronchoalveolar lavages (BAL), bronchial washings (BW), exhaled air condensates (EAC), blood specimen and urine specimen.	Sonstiges: BAL Patients with idiopathic and non idiopathic interstitial lung diseases Sonstiges: BW Patients with idiopathic and non idiopathic interstitial lung diseases Sonstiges: EAC Patients with idiopathic and non idiopathic interstitial lung diseases Sonstiges: blood specimen Patients with idiopathic and non idiopathic interstitial lung diseases Sonstiges: Urine specimen Patients with idiopathic and non idiopathic interstitial lung diseases
Non idiopathic intertitial diseases " Control group ": patients suffering from interstitial lung diseases of known aetiologies, such as hypersensibility pneumonitis, infectious or cancerous interstitial diseases and interstitial diseases caused by drug reactions. Nanoparticles (NP) loads will be measured on Bronchoalveolar lavages (BAL), bronchial washings (BW), exhaled air condensates (EAC), blood specimen and urine specimen.	Sonstiges: BAL Patients with idiopathic and non idiopathic interstitial lung diseases Sonstiges: BW Patients with idiopathic and non idiopathic interstitial lung diseases Sonstiges: EAC Patients with idiopathic and non idiopathic interstitial lung diseases Sonstiges: blood specimen Patients with idiopathic and non idiopathic interstitial lung diseases Sonstiges: Urine specimen Patients with idiopathic and non idiopathic interstitial lung diseases

Gruppe / Kohorte

Intervention / Behandlung

Idiopathic interstitial diseases

" Test group ": patients suffering from idiopathic interstitial lung diseases including sarcoidosis and idiopathic pulmonary fibrosis.

Nanoparticles (NP) loads will be measured on Bronchoalveolar lavages (BAL), bronchial washings (BW), exhaled air condensates (EAC), blood specimen and urine specimen.

Sonstiges: BAL